Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Syndax Pharmaceuticals ( (SNDX) ) has shared an announcement.
On January 12, 2026, Syndax Pharmaceuticals reported preliminary, unaudited financial results for the fourth quarter and full year 2025, highlighting strong commercial uptake of its two recently launched products and progress toward profitability. Revuforj generated approximately $44 million in net revenue in the fourth quarter and $125 million for 2025, with a 38% sequential quarterly revenue increase following its October 24, 2025 FDA approval in relapsed or refractory NPM1-mutant AML and a roughly 35% rise in prescriptions, while also earning the 2025 Scrip Awards “Best New Drug” accolade and advancing into multiple Phase 3 and access-expansion programs. Niktimvo delivered about $56 million in fourth-quarter and $152 million in full-year 2025 net revenue, from which Syndax expects to recognize 25–30% as its share of net revenue when full-year results are reported, underpinning a growing royalty and profit-share stream from its collaboration with Incyte. The company ended 2025 with roughly $394 million in cash, cash equivalents and marketable securities and guided to about $400 million in 2026 operating expenses (excluding non-cash stock compensation), stating that its current cash plus anticipated product revenue and interest income are expected to fund operations through the transition to profitability, while it prioritizes revenue growth from Revuforj and Niktimvo and executes on a broad set of 2026 clinical milestones, including Phase 2 and Phase 3 trials in idiopathic pulmonary fibrosis and frontline acute leukemia.
The most recent analyst rating on (SNDX) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Syndax Pharmaceuticals stock, see the SNDX Stock Forecast page.
Spark’s Take on SNDX Stock
According to Spark, TipRanks’ AI Analyst, SNDX is a Neutral.
The score is held back primarily by weak financial performance (large losses, heavy cash burn, and higher leverage despite improving revenue). Offsetting this are favorable technical momentum and a strong earnings-call backdrop driven by product traction and an FDA approval expanding the market opportunity.
To see Spark’s full report on SNDX stock, click here.
More about Syndax Pharmaceuticals
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its key FDA-approved products include Revuforj (revumenib), an oral first-in-class menin inhibitor for certain relapsed or refractory acute leukemias, and Niktimvo (axatilimab-csfr), a first-in-class CSF-1R-blocking monoclonal antibody approved for chronic graft-versus-host disease, with an active pipeline of trials aimed at expanding indications and frontline use across hematologic malignancies and related conditions.
Average Trading Volume: 2,557,963
Technical Sentiment Signal: Buy
Current Market Cap: $1.86B
See more insights into SNDX stock on TipRanks’ Stock Analysis page.